AURA — AURA BIOSCIENCES Income Statement
0.000.00%
Last trade - 00:00- $415.31m
- $253.45m
- 28
- 20
- 41
- 18
Annual income statement for AURA BIOSCIENCES, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 22.2 | 35.3 | 60.3 | 85 | 96.1 |
| Operating Profit | -22.2 | -35.3 | -60.3 | -85 | -96.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -22.2 | -35.3 | -58.8 | -76.3 | -86.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -22.2 | -35.3 | -58.8 | -76.4 | -86.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.2 | -35.3 | -58.8 | -76.4 | -86.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -30.1 | -46.2 | -58.8 | -76.4 | -86.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.06 | -1.58 | -1.95 | -1.93 | -1.75 |